Corona Remedies Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹344(32.39%)
Premium (ELP)
Corona Remedies Limited's successfully transitioned to public market status with its listing on NSE, BSE on Dec 15, 2025. The IPO mobilized 61,71,102 Shares in cumulative capital, including TBD for corporate expansion and ₹655.37 Cr for shareholder liquidity management.
The public offering was conducted within the price parameters of ₹1,008 to ₹1,062, with minimum investment lots of 14 shares. subscription activity between Dec 08, 2025 and Dec 10, 2025 demonstrated market reception to the company's valuation and growth narrative.
The allotment process concluded on Dec 11, 2025, finalizing share distribution to successful bidders. The listing represents a transformational event, providing the company with enhanced market visibility, regulatory compliance framework, and access to diversified investor capital.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Corona Remedies Limited, incorporated in August 2004, is a pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas including women’s healthcare, cardiology, pain management, urology, and multispecialty segments. As of December 2024, its portfolio includes 67 brands covering women’s health, cardio-diabetic care, pain relief, urology, and multispecialty products such as vitamins, minerals, nutrition, gastrointestinal, and respiratory medications. The company has established a strong pan-India presence with 2,598 medical representatives across 22 states, ensuring deep engagement with healthcare professionals and hospitals. It operates two manufacturing facilities in Gujarat, supporting its production and quality-focused growth strategy in the Indian Pharmaceutical Market.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Leading Market Growth Position: The company is the second fastest-growing among the top 30 pharmaceutical players (MAT 2022–2025), well-positioned to benefit from India’s expanding pharmaceutical demand.
- Diversified & Scalable Product Range: Successfully developing multiple “engine brands” across key therapy areas—women’s health, cardio-diabetic, pain, and urology—supports sustainable long-term growth.
- Extensive Pan-India Sales Network: A broad national sales and marketing network targeting specialist doctors and mid-income patients drives prescription growth above the overall market rate.
- High Reliance on Key Therapy Areas: More than 60% of revenue is generated from women’s health, cardio-diabetic, and pain management segments; underperformance or intensified competition in these areas may hinder growth.
- Concentration in Major Engine Brands: 27 primary “engine brands” account for over 70% of domestic sales; any decline in top brands like B-29 or Myoril could significantly impact performance.
- Dependence on Indian Market: Over 96% of revenue comes from India; weak domestic demand or delays in international expansion could adversely affect financial stability.
- Dr. Kirtikumar Laxmidas Mehta
- Niravkumar Kirtikumar Mehta
- Ankur Kirtikumar Mehta
Corona Remedies Limited
Bigshare Services Private Limited